Tirzepatide
Tirzepatide is unique because it’s the first combination of two classes of medications: a glucagon-like peptide-1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Tirzepatide is known as a dual GLP-1/GIP receptor agonist. As a dual-acting peptide, Tirzepatide stimulates insulin secretion, inhibits glucagon secretion, slows down gastric emptying and increases satiety. It signals to the brain that you’re full — so you eat less. It slows the movement of food through your stomach — so you feel full longer.
Like Semaglutide, it is usually given as a weekly injection. Other similar injectable weight loss medications only mimic one incretin — GLP-1. Because tirzepatide acts like two incretins, it can cause more weight loss than current alternatives.
Pricing
Contact for pricing.
Tirzepatide vs Semaglutide
- The FDA does not verify the safety, effectiveness or quality of compounded drugs
- Both are classified as GLP-1 receptor agonists, which means they work by mimicking the effects of a naturally occurring hormone in the body that helps regulate blood sugar and appetite.
- Both medications have been shown to be very effective in promoting weight loss in clinical trials
- Tirzepatide is known as a dual-acting peptide, since it is a GLP-1 and a GIP receptor agonist
- Tirzepatide is a newer medication and has been shown to be more effective in promoting weight loss compared to semaglutide (in clinical trials, patients taking tirzepatide lost on average about twice as much weight as patients taking semaglutide).
Ready to optimize your health?
Tirzepatide in Weston, FL — Frequently Asked Questions
Common questions about tirzepatide (Mounjaro/Zepbound) medical weight loss at DMHealth, our Weston clinic, and Florida telehealth.
What is tirzepatide (Mounjaro and Zepbound)?
Tirzepatide is a once-weekly injectable medication that activates two gut-hormone receptors, GIP and GLP-1. It is sold under the brand names Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management). At DMHealth it is prescribed only after a medical evaluation by our provider.
Is tirzepatide FDA-approved?
Yes. The FDA approved Mounjaro for type 2 diabetes in 2022 and Zepbound for chronic weight management in adults in 2023. Any use outside an approved indication is determined by your provider on an individual basis.
How is tirzepatide different from semaglutide?
Semaglutide (Ozempic/Wegovy) activates one receptor, GLP-1. Tirzepatide activates two, GIP and GLP-1. Your DMHealth provider helps determine which medication is more appropriate for your health history and goals.
Who is a candidate for tirzepatide at DMHealth?
Candidacy is decided during a medical consultation and depends on your BMI, health history, current medications, and goals. Tirzepatide is not appropriate for everyone; our provider reviews your history and any needed labs before prescribing.
How does the DMHealth telehealth process work?
You complete an online intake and a telehealth consultation with our provider, we review your medical history and any needed lab work, and if appropriate, a personalized plan is prescribed with ongoing follow-up. All care is provider-led and supervised by our Medical Director.
Can I get tirzepatide in person in Weston, FL?
Yes. DMHealth serves patients in person at our Weston clinic at 2700 Glades Cir Ste 136 and by telehealth across Florida, so you can be seen locally in Weston or from anywhere in the state.
What are the common side effects of tirzepatide?
The most common side effects are gastrointestinal, such as nausea, diarrhea, constipation, or reduced appetite, and often ease over time. Your provider reviews risks, side effects, and how to manage them before you start.
How much does tirzepatide cost at DMHealth?
Pricing depends on your personalized plan and dosing, which we review with you during your consultation. Book a consultation to get a plan and pricing for your situation.
Related services at DMHealth: Semaglutide weight loss in Weston · Medical weight loss programs · Peptide therapy
Medically reviewed by: Diana Medina, MMS, PA-C — Florida-licensed Physician Assistant
Medical Director: Luis Campillo, MD
Last reviewed: May 20, 2026
This page is for educational purposes only and does not constitute medical advice. All treatments require an individualized medical evaluation. DMHealth provides services via telehealth to Florida residents under the medical supervision of Luis Campillo, MD, in accordance with Florida Statutes § 458.347 governing physician assistant practice. Some statements have not been evaluated by the U.S. Food and Drug Administration; products mentioned are not intended to diagnose, treat, cure, or prevent any disease.